Holen Sie sich die Stockscreener-App
2.705
0.93%
0.025
Vorhandelsmarkt:
2.70
-0.005
-0.18%
Schlusskurs vom Vortag:
$2.68
Offen:
$2.67
24-Stunden-Volumen:
36,527
Relative Volume:
0.33
Marktkapitalisierung:
$267.64M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-60.14M
KGV:
-3.1674
EPS:
-0.854
Netto-Cashflow:
$-68.17M
1W Leistung:
+0.19%
1M Leistung:
-20.44%
6M Leistung:
-31.86%
1J Leistung:
-42.93%
1-Tages-Spanne:
$2.60
$2.76
1-Wochen-Bereich:
$2.60
$3.0699
52-Wochen-Spanne:
$2.25
$5.14
Ac Immune Sa Stock (ACIU) Company Profile
Vergleichen Sie ACIU mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
2.705 | 267.64M | 0 | -60.14M | -68.17M | -0.7095 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.65 | 105.75B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.68 | 78.76B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
632.04 | 37.79B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.50 | 31.28B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.77 | 27.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-31 | Eingeleitet | BTIG Research | Buy |
| 2019-02-01 | Herabstufung | UBS | Buy → Neutral |
| 2019-01-04 | Eingeleitet | UBS | Buy |
| 2018-04-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-23 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2016-10-18 | Eingeleitet | Credit Suisse | Outperform |
| 2016-10-18 | Eingeleitet | Jefferies | Buy |
| 2016-10-18 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Ac Immune Sa Aktie (ACIU) Neueste Nachrichten
AC Immune SA's (NASDAQ:ACIU) last week's 11% decline must have disappointed retail investors who have a significant stake - Simply Wall St
AC Immune Announces Key Executive Promotions to Strengthen R&D Leadership - TipRanks
AC Immune (NASDAQ:ACIU) Stock Crosses Below 200-Day Moving AverageHere's What Happened - MarketBeat
AC Immune announces interim safety, tolerability data from ABATE Phase 1b/2 - Yahoo Finance
AC Immune's ABATE Trial Shows Positive Safety Data in Down Syndrome - Investing.com Canada
AC Immune Announces Promising Safety Data for Down Syndrome Therapy - TipRanks
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome - GlobeNewswire
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome - GlobeNewswire Inc.
AC Immune Q3 2024: Strong Progress and Financial Turnaround - TipRanks
HC Wainwright Reaffirms “Buy” Rating for AC Immune (NASDAQ:ACIU) - Defense World
AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit - Clinical Trials Arena
AC Immune (NASDAQ:ACIU) Given "Buy" Rating at HC Wainwright - MarketBeat
AC Immune reports interim results from Phase 2 trial of ACI-7104.056 - Yahoo Finance
AC Immune (ACIU) Sees Stock Boost Following Positive Trial Data - Stocks Telegraph
Short Interest in AC Immune SA (NASDAQ:ACIU) Increases By 23.5% - MarketBeat
AC Immune SA (NASDAQ:ACIU) Short Interest Up 23.5% in October - Defense World
AC Immune stock jumps 20% on data for Parkinson's disease drug (NASDAQ:ACIU) - Seeking Alpha
S&P 500 Moves Lower; US Crude Oil Inventories Increase - Benzinga
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients - Benzinga
AC Immune Phase II ACI-7104.056 success in Parkinson’s - The Pharma Letter
AC Immune's Parkinson's vaccine shows promise in early trial - Investing.com India
AC immune announces positive trial results for early Parkinson’s treatment - PharmaTimes
AC Immune’s Promising Trial Results for Parkinson’s Therapy - TipRanks
Immunotherapy in Early Parkinson’s Disease Posts Positive Interim Results from Phase 2 Study - Precision Vaccinations
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease - The Manila Times
AC Immune's Parkinson's vaccine shows promise in early trial By Investing.com - Investing.com UK
AC Immune's Parkinson's Drug Shows 16x Higher Antibody Levels in Phase 2 Trial | ACIU Stock News - StockTitan
AC Immune to Present at Jefferies Healthcare Conference: Key Investor Updates Coming | ACIU Stock News - StockTitan
AC Immune to Present at the Jefferies 2024 London Healthcare Conference - Informazione.it
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights - The Manila Times
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board - The Manila Times
AC Immune SA Beat Analyst Profit Forecasts, And Analysts Have New Estimates - Yahoo Finance
Leerink Partnrs Increases Earnings Estimates for AC Immune - Defense World
FY2024 EPS Estimates for AC Immune Lifted by Leerink Partnrs - MarketBeat
FY2024 EPS Estimates for AC Immune Boosted by HC Wainwright - MarketBeat
HC Wainwright Reaffirms Buy Rating for AC Immune (NASDAQ:ACIU) - Defense World
Brokers Set Expectations for AC Immune FY2027 Earnings - MarketBeat
HC Wainwright Reiterates "Buy" Rating for AC Immune (NASDAQ:ACIU) - MarketBeat
AC Immune SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
AC Immune: Q3 Earnings Snapshot - San Francisco Chronicle
AC Immune reports Q3 EPS CHF 0.05 vs (CHF 0.18) last year - TipRanks
AC Immune SA Reports Profitable Q3 2024 Results - TipRanks
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - The Manila Times
Will ABATE Trial Data Lift AC Immune's Stock Price? - RTTNews
Assenagon Asset Management S.A. Has $846,000 Stock Position in AC Immune SA (NASDAQ:ACIU) - MarketBeat
Short Interest in AC Immune SA (NASDAQ:ACIU) Decreases By 7.4% - MarketBeat
AC Immune SA (NASDAQ:ACIU) stock most popular amongst individual investors who own 32%, while private equity firms hold 29% - Yahoo Finance
What To Expect From AC Immune SA (ACIU) Q3 2024 Earnings - Yahoo Finance
Roche leaves Alzheimer partnership with UCB - European Biotechnology News
Finanzdaten der Ac Immune Sa-Aktie (ACIU)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.50%
1.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):